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Abstract: The process of biomarker discovery is typically lengthy and costly, involving the phases
of discovery, qualification, verification, and validation before clinical evaluation. Being able to
efficiently identify the truly relevant markers in discovery studies can significantly simplify the
process. However, in discovery studies the sample size is typically small while the number of
markers being explored is much larger. Hence discovery studies suffer from sparsity and high di-
mensionality issues. Currently the state-of-the-art methods either find too many false positives or
fail to identify many truly relevant markers. In this paper we develop a likelihood ratio-based ap-
proach and aim for accurately finding the truly relevant protein markers in discovery studies. Our
method fits especially well with discovery studies because they are mostly balanced design due to
the fact that experiments are limited and controlled. Our approach is based on the observation that
the underlying distributions of expression profiles are unimodal for those irrelevant plain mark-
ers. Our method has asymptotic chi-square null distribution which facilitates the efficient control
of false discovery rate. We then evaluate our method using both simulated and real experimental
data. In all the experiments our method is highly effective to discover the set of truly relevant
markers, leading to accurate biomarker identifications with high sensitivity and low empirical false
discovery rate.
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1 Introduction
Discovering potential protein biomarkers with clinical values is regularly a long, costly, and chal-
lenging process [Rifai et al., 2006]. Each phase of the study (i.e., discovery, qualification, verifi-
cation, and validation) costs substantial amount of time and resources. In this paper we develop
a statistical method to expedite the process. We aim for accurately identifying the truly relevant
markers at the discovery phase, which can be directly entered for verification or even validation
phrase. Figure 1 illustrates our objective.
Figure 1: The typical process of biomarker discovery.
Here we focus on proteomics studies. Because following a large number of genomics studies,
scientists realized that there is not necessarily high correlation between genes and proteins pro-
files, which implies that proteomics provides important complementary information to genomics
[Pandey et al., 2000]. Moreover, since most of the drugs are directed to interact with proteins, the
protein markers are as informative as gene markers.
In proteomics, mass spectrometry is considered the most productive and reliable technique for
protein quantification. In particular, data-independent acquisition (DIA) [Carvalho et al., 2010,
Gillet et al., 2012] has been proven to produce high quality and reproducible throughput. Hence
DIA is a very effective technique for protein quantification in discovery studies. Currently there
are a number of established univariate and multivariate methods being applied to identify potential
biomarkers in mass spectrometry proteomics.
LIMMA [Smyth, 2004], SAM [Tusher et al., 2001], and Rank Products [Breitling et al., 2004]
are popular univariate methods. LIMMA fits linear models to each marker, then applies empiri-
cal Bayes method to form moderated t-statistics. The moderated t-statistics are used to rank and
select the markers. SAM assigns a score to each marker based its “relative difference”. Mark-
ers with scores larger than a threshold value is selected. Rank Products is a non-parametric ap-
proach, based on ranks of fold changes. Markers with the smallest values are selected. Mean-
while Principal Component Analysis (PCA), Penalized Logistic Regression (PLR), Partial Least
Square-Discriminant Analysis (PLS-DA), and Support Vector Machine (SVM) are well-known
multivariate methods regularly used in this field as well.
In discovery studies the sample size is small while the number of markers explored is large,
owing to the high throughput of DIA. Nowadays there are typically thousands of protein markers
quantified by DIA experiments, out of which usually only 10-50 markers are truly relevant. Dis-
covery studies encounter sparsity and high dimensionality issues. The above univariate methods
are not effective since they often identify too many false positives due to sparsity issue, leading
to an unacceptable high empirical false discovery rate (FDR). For example this is observed in
multiple testing procedure. On the other hand the multivariate methods mentioned above are not
effective either because of high dimensionality issue. They often identify too few of the truly rel-
evant markers, leading to an unacceptable low sensitivity. The multivariate methods mentioned
above have powerful model structures. Because they only need a small number of markers to
achieve high classification accuracy, these methods stop identifying more relevant markers once
they reach sufficiently accurate classification results. High FDR results in considerable waste of
time and resource at the subsequent phases, while low sensitivity leads to many unidentified useful
biomarkers. Therefore, there is a genuine need of a novel statistical method capable of accurately
identifying the correct set of truly relevant protein markers at the discovery phase.
Here we develop a likelihood ratio based approach. In this paper, we consider the scenario
where are two conditions, such as disease vs. normal. Since experiments at the initial discovery
phase are mostly controlled, our method focuses on data from balanced design given two condi-
tions. Two discriminant statistics are developed based on the likelihood ratio idea. One is for the
sample size greater or equal to five per condition. The other one is for very small sample size, less
than 5 per condition. The main idea behind our likelihood ratio approach is that the expression
profiles for the irrelevant plain markers follow unimodal distributions, where those for the truly
relevant markers follow bimodal distributions. The discriminant statistics are the likelihood ratios
of a bimodal distribution versus a unimodal distribution, calculated for every protein. For larger
sample size, the bimodal distribution is approximated by a mixture of normals, and the unimodal
distribution is approximated by a univariate normal. For very small sample size, we use kernel
method to estimate the distribution of the expression profiles, then compute the ratio of the ker-
nel estimate versus a univariate normal. Our likelihood ratio statistics have large values for the
truly relevant markers, and small values for the plain markers. Our proposed method is robust to
deviations from normality as long as the null expression profiles are unimodal, even though the
likelihood of normal distribution is used. Notice with the multiple t-tests, the null and alternative
hypotheses compare the means of two conditions. If the null hypothesis is rejected, the two condi-
tions have different mean values. Essentially this indicates that marker does not follow a unimodal
distribution. Our approach goes beyond simply considering the mean values. We explicitly esti-
mate or approximate the likelihood functions under the null and alternative hypotheses. Hence our
approach achieves a much more accurate result.
We compare our method with the aforementioned univariate and multivariate methods for mass
spectrometry-based proteomics studies. Evaluations are performed with experimental datasets
where truly relevant markers are known from controlled mixtures or previous literature, as well
as simulated datasets. The paper is organized as follows. Section 2 describe our likelihood ratio
based approach for precise protein biomarker discovery. Section 3 shows the experimental results
for our approach compared with other methods. Section 4 concludes the paper.
2 A Likelihood Ratio Approach
In this paper we develop two discriminant statistics which accurately differentiate the true markers
from the plain markers. We first examine the distributions of expression profiles of plain markers,
as shown in Figure 2. These are proteins from HRM data, discussed in Section 3. Plain protein
markers from other experimental datasets generally share this property, i.e., their expression pro-
files follow unimodal distributions. We also examine the distributions of expression profiles of the
truly relevant markers, as shown in Figure 3. These are also proteins from HRM data. True protein
markers from other experimental datasets generally follow a bimodal distribution too, given there
are two conditions.
Figure 2: The expression distributions for four plain markers in HRM data.
Figure 3: The expression distributions for four true markers in HRM data.
We discover that the distributions of expression profiles are usually unimodal for plain markers,
and bimodal for truly relevant markers. In addition, we observe that the distributions of expression
profile for truly relevant markers can be approximated by a mixtures of normals, whereas for plain
markers it can be approximated by a univariate normal, given enough sample size to estimate the
normal parameters. Without enough sample size, we apply kernel method to estimate the bimodal
density.
2.1 A Discriminant Statistic for ni ≥ 5
Let n1 and n2 be the sample size for each condition, and N = n1 + n2 be the total sample size.
The mixture proportions of the two conditions are the sample proportions, ni/N . We develop a
likelihood ratio based discriminant statistic for larger sample size, where ni ≥ 5, i = 1, 2. It
is the ratio of a mixture of normals’ density versus a univariate normal density. With relatively
larger sample sizes, we approximate the bimodal distribution using a mixture of normals, and the
unimodal distribution using a univariate normal. The likelihood ratio clearly differentiates the true
markers from the plain markers.
Table 1: Data Layout and Notation for Condition i, i = 1, 2
Protein 1 ... Protein p
Sample 1 xi11 ... x
i
1p
...
...
...
...
Sample ni xin1,1 ... x
i
n1,p
Table 1 shows a sample data layout, with i = 1, 2. Let µ1 and µ2 be the means of each
normal distribution composing the mixture while σ21 and σ
2
2 are their respective variances. The
mixing coefficients are n1
N
and n2
N
. Let µ and σ2 be the mean and variance of the pooled univariate
normal. The discriminant statistic is calculated for every protein. Assume there are p proteins. The
discriminant statistic Rj for the j−th protein, j = 1, ..., p, is calculated as follows.
Rj =
sup{L(mixture of normals)}
sup{L(univariate normal)}
=
sup
{
L
[
µ1, µ2, σ
2
1, σ
2
2|n1, x11j, ..., x1n1,j, n2, x21j, ..., x2n2,j
]}
sup
{
L
[
µ, σ2|N, x11j, ..., x1n1,j, x21j, ..., x2n2,j
]} (1)
Below is the likelihood of a mixture of normals.
L
[
µ1, µ2, σ
2
1, σ
2
2|n1, x11j, ..., x1n1,j, n2, x21j, ..., x2n2,j
]
=
2∏
i=1
( ni∏
k=1
( 2∑
l=1
nl
N
√
2piσ2l
exp{(x
i
kj − µl)2
2σ2l
})) (2)
Below is the likelihood of the pooled normal.
L
[
µ, σ2|N, x11j, ..., x1n1,j, x21j, ..., x2n2,j
]
=
2∏
i=1
ni∏
k=1
( 1√
2piσ2
exp{(x
i
kj − µ)2
2σ2
}) (3)
The maximum of the likelihood function is computed by plugging in the maximum likelihood
estimates (MLE) of parameters to the likelihood function. Let µˆ1, µˆ2, σˆ21 , and σˆ
2
2 be the MLEs.
MLEs are obtained by maximizing the corresponding likelihood functions. The MLEs have closed
form [Bilmes, 1998] as follows. We have the MLEs for the pooled normal as follows.
µˆ =
∑
i,k,j x
i
kj
N
,
σˆ2 =
∑
i,k,j(x
i
kj − µˆ)2
N
.
Let f(xikj, µl, σ
2
l ) = exp{
(xikj−µl)2
2σ2l
}/√2piσ2l . l = 1, 2. Let
pl(x
i
kj) =
f(xikj, µl, σ
2
l )∑2
l=1(f(x
i
kj, µl, σ
2
l )nl)
.
The MLEs for the mixture of normals given the mixing coefficients n1
N
and n2
N
are the following,
l = 1, 2.
µˆl =
∑
i,k,j(pl(x
i
kj)× xikj)∑
i,k,j pl(x
i
kj)
,
σˆ2l =
∑
i,k,j(pl(x
i
kj)× (xikj − µˆl)2)∑
i,k,j pl(x
i
kj)
The discriminant statistic, Rj , for the j−th protein is the following.
Rj =
L
[
µˆ1, µˆ2, σˆ
2
1, σˆ
2
2|n1, x11j, ..., x1n1,j, n2, x21j, ..., x2n2,j
]
L
[
µˆ, σˆ2|N, x11j, ..., x1n1,j, x21j, ..., x2n2,j
] (4)
Consequently, from (4) we can tell that Rj is expected to have a large value if protein j is a truly
relevant marker. Otherwise, Rj is expected to be small.
2.2 Asymptotic Property of Rj
Here we derive the asymptotic property of the statistic Rj under the null hypothesis, which enables
us to quantify the statistical significance on each protein provided sample size is sufficient. The
discriminant statistic Rj can be thought of as the statistic for testing whether the j−th protein truly
has expression profiles correlate with conditions or not, with the following null and alternative
hypotheses.

H0 : The j−th protein is a plain marker
(unimodal approximated by univariate normal)
Ha : The j−th protein is a relevant marker
(bimodal approximated by a mixture of normals)
Hence we write the hypotheses in terms of notations as follows.{
H0 : µ1 = µ2 and σ
2
1 = σ
2
2
Ha : µ1 6= µ2 or σ21 6= σ22
(5)
The statistic for the j−th protein Rj = sup[L(Ha)]/ sup[L(H0)] is specified in Equation 4. We
note that Rj is the likelihood ratio statistic for testing between full and reduced models. Therefore,
the quantity 2 ln(Rj) is the deviance of the goodness-of-fit test. As the asymptotic property of the
deviance had been known, we know that the asymptotic null distribution of 2 ln(Rj) is chi-square.
Note that the degrees of freedom is the difference in dimension of parameter spaces between Ha
and H0. In particular, the statistic 2 ln(Rj) has 2 degrees of freedom because its corresponding
hypotheses in Equation (5) has 4 free parameters in the distribution under Ha and only 2 in the
distribution under H0. We have
2 ln(Rj) = 2 ln
{sup[L(Ha)]
sup[L(H0)]
} d−→ χ22 under H0 (6)
Although the property of 2 ln(Rj) is asymptotic in theory, in practice it takes around 10 to 30
samples per condition to converge to chi-square, assuming a balanced design (n1 = n2 = n) as it
is the most common case in discovery studies. Table 2 shows the empirical tail probability P [Rj >
χ22,α], with α = 0.01, 0.05, 0.1, using simulated data discussed in Section 3.2. It demonstrates that
the convergence of 2 ln(Rj) to χ22 is valid and efficient. In general, this convergence is satisfactory
when there are at least 10 samples per condition (n≥10).
Table 2: The empirical tail probability ofRj with increasing sample sizes. This verifies the asymp-
totic property of Rj in (6) and shows the fast convergence rate.
ni P [Rj > χ
2
2,0.01] P [Rj > χ
2
2,0.05] P [Rj > χ
2
2,0.10]
3 0.22 0.30 0.33
5 0.10 0.15 0.21
8 0.04 0.09 0.16
10 0.03 0.08 0.13
15 0.02 0.07 0.11
20 0.02 0.05 0.10
30 0.01 0.05 0.10
2.3 Alternative Statistic for Very Small Sample Size ni < 5
When there are at least five samples per condition, the sample means and the sample variances
are sufficiently accurate estimates. Consequently we obtain a reasonable likelihood function of a
mixture normal to be used in the discriminant statistic in Section 2.1. However discovery studies
usually face small sample sizes. Sometimes there are less than five sample per condition, which
leads to inaccurate sample means and sample variances. When the sample size is too small, the
statistic in Section 2.1 does not perform well. We notice that plain markers have unimodal ex-
pression file distributions is a strong identifying feature. Here we develop an alternative statistic
which performs well for very small sample size, with n1 = n2 = n < 5. The idea for very small
sample size is to compare the estimated empirical distribution of a protein’s expression profile with
a pooled univariate normal, where the samples from two conditions are combined. The null hy-
pothesis is that the particular protein in question is plain. We use kernel density estimation method
for approximating the empirical distribution of protein expression profiles, which provide results
quite sensitive to non-unimodal patterns. Notice for larger sample size, the estimated empirical
distribution can be simplified to an approximate mixture of normals.
For the j−th protein, we estimate its expression profile distribution’s density function using
the normal kernel as follows.
gˆhj(x) =
1
nhj
2∑
i=1
n∑
k=1
K(
x− xikj
hj
), (7)
where that n1 = n2 = n is the sample size of each condition; xikj is the expression intensity as
displayed in Table 1; K(·) is the density of standard normal; and hj is the optimal bandwidth for
the j−th protein derived according to minimum mean integrated squared error as follows.
hj = argmax
hj
E{
∫
[gˆhj(x)− gj(x)]2dx}, (8)
where gˆhj(x) is the kernel density estimation from (7) with bandwidth of h whilst gj(x) is the
(unknown) true density of expression profile.
As opposed to simply testing the parameters when the sample size is at least five per condition,
as shown in (5), here we compare two distributions. For the j−th protein density function ghj(x),
let Ghj(x) be the corresponding cumulative distribution function (CDF). Under the alternative
hypothesis Ghj(x) does not follow a unimodal distribution. Let Fj(x) be the CDF of the pooled
univariate normal under the null hypothesis that the observed expressions are drawn from a single
univariate normal distribution. The null and the alternative hypothesis are written as follows.{
H0 : Ghj(x) = Fj(x) (The j−th protein is a plain marker)
Ha : Ghj(x) 6= Fj(x) (The j−th protein is truly relevant)
We then use the Kolmogorov-Smirnov (K-S) method for testing the hypotheses. K-S test uses
the maximum difference between the CDF of kernel density and that of univariate normal, both
evaluated at each observed expression, as the test statistic.
Dj = max
i,k
|Ghj(xikj)− F (xikj)| (9)
Massey [Massey Jr, 1951] claimed that K-S test is superior to the chi-square test especially
in cases of small sample size. Since the normal CDF Fj(x) in hypotheses (2.3) is not specified
in advance (i.e., the mean and variance are estimated from the data), the significance level and
p-value of K-S test should be derived carefully. Hence, we apply the method developed in Lil-
liefors [Lilliefors, 1967] to obtain the p-value as mean and variance of univariate normal are not
specified in advance but estimated from the sample.
3 Experimental Results
3.1 Experimental Datasets
The following two experimental datasets are used to evaluate the performance of our approach in
Section 3. In this section, we use two criteria to compare different approaches. One is sensitivity,
which is the ratio of the number of truly relevant markers among the selected markers vs the actual
number of truly relevant markers. The other is FDR, which is the ratio of false positives among the
selected markers vs the number of selected markers. The truly relevant protein markers are known
in the two datasets. Hence we are able to compare the sensitivity and FDR of different approaches
including ours.
Hyper Reaction Monitoring (HRM) Data: Hyper Reaction Monitoring (HRM) is a novel DIA
technique proposed by [Bruderer et al., 2015] where spectral libraries were based on normalized
retention time for data extraction. The main contribution of [Bruderer et al., 2015] is to show
the capability of their DIA technique. Compared with DDA technique, they demonstrated the
increased capability that DIA technique brings to protein biomarker discovery. In order to show
that HRM is superior to the established old-generation DDA technique, they conducted experiment
where 3785 proteins were quantified and 12 of them were known to be correlated with conditions.
This is a typical setup for discovery study in that there are 8 conditions with 3 samples in each
condition. Later in our experiments, we merge the samples from similar conditions so that there
are 2 conditions with 12 samples each.
Yeast Data: SWATH-MS [Selevsek et al., 2015] was invented as an innovative DIA experiment,
which combined the strength of DIA and target data analysis for more throughput with high ac-
curacy. In the interest of proving the competence of SWATH-MS they quantified protein markers
on Saccharomyces cerevisiae with osmotic stress imposed over time. There are 6 time points,
regarded as conditions, and 3 samples in each condition. In total, 2602 proteins were quantified
in which 50 were known to be regulated in response to osmotic stress. In addition, proteins re-
sponding to osmatic stress are mainly associated with arbohydrate and amino acid metabolism.
Therefore, the ability SWATH-MS provides to recover known biomarkers shows that DIA data has
promising potential to assist in discovering relevant protein markers.
This experimental data is another typical discovery study, where many markers are explored
while sample size is limited. In our experiments, we again merge the samples from the first 3
time points, and those from the last 3 time points. We then have 2 condition where there are 9
samples each. Merging the samples is reasonable here since the change of protein expressions, if
any, happens gradually as the experiment progressed.
Figure 4: Ordered values of the statistic Rj . The largest 100 are shown.
3.2 Simulated Datasets
We also simulate a large number of datasets with different configurations to evaluate our approach.
In general, in each simulation run 1000 protein markers are generated, and the expression pro-
files of each protein are simulated according to the following steps. Note that the parameters we
use are the estimated values of those from the data sets acquired and processed by OpenSWATH
[Ro¨st et al., 2014], where proteins were under the matrices of water and human. Water is the
simplest matrix among them, with clean signals, whereas human is the most complex under con-
siderable interference. Simulated data points are denoted as X ikj , which is the expression intensity
for the j−th protein of the k−th subject within the i−th condition. An example of simulated data
layout is shown in Table 1.
1. Step 1. Generate the expression intensityX ikj according to the following equation ([Ro¨st et al., 2014]).
X ikj = µ+ Ci + S(C)k(i) + Fj + 
i
kj
2. Step 2. In the equation above Ci stands for the main effect of a condition, S(C)k(i) the effect
of each subject within a condition, and Fj the main effect of each protein. We then generate
the source of variations for the true markers and plain markers as follows. We simulate 2
conditions, i = 1, 2.
For true markers C1 6= C2. For plain markers C1 = C2. Then the other items in the above
equation are simulated for normal distributions as follows.
S(C)k(i) ∼ N(0, σ2S),
Fj ∼ N(0, σ2F ),
ikj ∼ N(0, σ2).
Figure 5: Ordered values of the statistic Rj . The largest 100 are shown.
3. Step 3. Set the parameter values according to [Ro¨st et al., 2014]. We have µ = 15, σ2S =
27.37, and σ2F = 0.98. The sample size for each condition and the number of proteins vary
in different simulation runs. The error term ikj’s variance depends on the matrices. We
have σ2 = 2.23 for human background, the most complex matrix; σ2 = 0.48 for water
background, the matrix with the smallest level of interference.
Figure 6: Ordered values of the statistic Dj . The largest 100 are shown.
3.3 Robust Performance Against Deviations from Normality
Although the two statistics in Section 2.1 are constructed as a ratio of a mixture distribution or
the empirical distribution versus a pooled univariate normal, they show robust performance with
Figure 7: Ordered values of the statistic Dj . The largest 100 are shown.
non-normal distributions too. Figure 2 shows the empirical expression profile distributions of
plain markers in HRM data. The most important feature of plain markers is that their expression
profile distributions are unimodal. Hence the fundamental idea behind our approach is to separate
bimodal distributions from unimodal distributions, which lead to accurate identification of true
markers. The underlying actual distributions do not need to strictly follow normality assumptions
for our approach to perform well. Here we demonstrate the robust performance of the two statistics
against strong deviations from normality.
In one experiment, we have 10 samples per condition. We simulate 1000 proteins as specified
in Section 3.2 but with different error term distributions, where there are 30 true markers and
970 plain markers. The error terms are simulated according to Cauchy distribution with location
parameter 15 and scale parameter 2 (Figure 4) and chi-square distribution with two degrees of
freedom (Figure 5). Cauchy distribution has much heavier tails than normal and chi-square with
two degrees of freedom is very skewed distribution. Plain markers have C1 = C2 = U where U is
randomly sampled following a uniform distribution over [1, 100]. The effect size is 3 fold for true
markers. The fold change is defined on log base 2 scale. True markers have C1 = log2(6) + U
and C2 = log2(2) + U where U is randomly sampled from a uniform distribution over [1, 10].
The resulting expression profile distributions for both plain markers and true markers are strongly
non-normal.
The proteins are ordered by their Rj values. The largest 100 proteins are shown in Figures 4
and 5. The ordered values of the statistic Rj , which works well for not-too-small sample size,
show a sudden drop after the largest values. We choose the cutoff for Rj at where the drop occurs.
This pattern is also observed from the two experimental datasets in Section 3.4. We select the
markers with Rj values larger than the cutoff. Based on this selection method, we are able to
accurately identify 1) the number of truly relevant markers; 2) the relevant markers themselves.
In another experiment we simulate 1000 proteins as in the first experiment, only there are 3
samples per conditions. The statistic Dj for very small sample size is used. Figures 6 and 7 show
the order values of Dj , the 100 largest ones, which exhibit the same pattern. With very small
sample size, we are still able to accurately identify the relevant markers.
3.4 High Sensitivity and Low FDR
Figure 8: Ordered values of the statistic Rj for Yeast Data. The largest 100 are shown.
Table 3: Sensitivity and empirical FDR for Yeast and HRM data
HRM data Yeast data
Sensitivity Empirical FDR Sensitivity Empirical FDR
LIMMA 12
12
= 1.00 14
26
= 0.54 51
51
= 1.00 36
87
= 0.41
RP 12
12
= 1.00 9
21
= 0.43 48
51
= 0.94 31
82
= 0.38
SAM 12
12
= 1.00 8
20
= 0.40 50
51
= 0.94 41
91
= 0.45
t-test 12
12
= 1.00 16
28
= 0.57 50
51
= 0.98 55
106
= 0.52
PCA 6
12
= 0.50 1
6
= 0.17 8
51
= 0.16 1
8
= 0.13
PLR 3
12
= 0.25 0
3
= 0 6
51
= 0.12 0
6
= 0
PLS-DA 7
12
= 0.58 0
7
= 0 11
51
= 0.22 1
12
= 0.08
SVM 7
12
= 0.58 0
8
= 0 15
51
= 0.29 1
16
= 0.06
Our Rj 1212 = 1.00
1
13
= 0.08 50
51
= 0.98 4
54
= 0.07
We apply the statistic Rj to the two experimental datasets, Yeast data and HRM data as dis-
cussed earlier. Figures 8 and 9 show the ordered values of Rj . Again we observe a sudden drop of
Rj values. We set the cutoff of Rj to be 2.5. We then select the proteins that have Rj values larger
than cutoff. In Table 3 we compare the commonly used univariate and multivariate methods with
our statistic Rj based on sensitivity and FDR. For univariate methods FDR cutoff is set at 0.05,
while for multivariate methods the algorithms stop based on their default stopping criteria. The
Figure 9: Ordered values of the statistic Rj for HM Data. The largest 100 are shown.
univariate methods select too many markers, and suffer from high empirical FDR. The multivari-
ate methods have strong model structures. They do not need all the relevant markers to achieve
high classification accuracy. Hence they select too few markers, leading to very low sensitivity.
Our approach, to cut off at where Rj values suddenly drop, returns superior sensitivity with very
low FDR.
Next we compare our approach with the commonly used methods in simulation studies. In
a single run we simulate 1000 proteins as specified in Section 3.2 with the error terms normally
distributed, where there are 30 true markers and 970 plain markers. Again plain markers have
C1 = C2 = U where U is randomly sampled following a uniform distribution over [1, 100]. The
effect size is 3 fold for true markers. True markers have C1 = log2(6) + U and C2 = log2(2) + U
where U is randomly sampled following a uniform distribution over [1, 10]. In one experiment we
have 10 samples per condition and conduct 50 runs, with the average sensitivity and the average
FDR shown in Table 4. In another experiment we have 3 samples per condition and conduct 50
runs, with the average sensitivity and the average FDR shown in Table 5.
Table 4: Average sensitivity and empirical FDR for water, human, yeast background with 10 sam-
ples per condition. FDR is set at 0.05 for univariate methods. Rj cutoff is 2.5
Water Human
Sensitivity Empirical FDR Sensitivity Empirical FDR
LIMMA 0.87 0.50 0.67 0.40
RP 0.73 0.41 0.80 0.33
SAM 0.90 0.44 0.77 0.43
t-test 0.70 0.29 0.50 0.40
PCA 0.17 0.20 0.13 0.25
PLR 0.40 0.25 0.33 0.1
PLS-DA 0.23 0.29 0.13 0.04
SVM 0.40 0.17 0.37 0.09
Our Rj 0.90 0.15 0.77 0.17
Table 5: Average sensitivity and empirical FDR for water, human, yeast background with 3 samples
per condition. FDR is set at 0.1 for univariate methods. Dj cutoff is 2.5
Water Human
Sensitivity Empirical FDR Sensitivity Empirical FDR
LIMMA 0.40 0.54 0.48 0.51
RP 0.53 0.43 0.55 0.58
SAM 0.37 0.40 0.40 0.40
t-test 0.23 0.57 0.43 0.41
PCA 0.37 0.37 0.19 0.13
PLR 0.30 0.13 0.13 0.16
PLS-DA 0.41 0.09 0.38 0.40
SVM 0.50 0.25 0.45 0.35
Our Dj 0.67 0.20 0.53 0.31
4 Conclusion and Discussion
Our approach is superior to the popularly applied methods univariate and multivariate methods
given reasonable sample size. Our approach shows good performance for very small sample size,
especially under water background. In addition, we notice that nowadays most of the experimental
designs have allowed us to merge samples from adjacent conditions (groups). At the end of the
day we may not have to rely on the alternative procedure for very small sample size cases.
Meanwhile, as the primary goal of this paper is to accurately identify relevant biomarkers in
discovery study, which is mostly balanced design with moderate or small sample size, the method
we propose is mainly for the balanced design given two conditions. Thus how to handle the data ac-
quired from highly unbalanced design under multiple conditions (more than two) with potentially
very small sample size for certain conditions is part of our future work.
The nature of discovery study combined with the advancement of DIA experiment result in
sparse and high dimensional data. It is known that popular univariate methods struggle under
sparsity and multivariate methods stumble under high dimensionality.
Nonetheless, our proposed likelihood-based statistic resolves the problem from a critical per-
spective – accurately estimates the number of truly relevant markers. This feature can effectively
resolves the aforesaid drawbacks from current methods.
From multiple experimental and simulated data sets we demonstrate that our approach is able
to accurately identify the set of truly relevant protein markers. The implication is that our proposed
method can simplify the unnecessarily lengthy and costly process of biomarker discovery without
compromising the findings of markers correlating with conditions.
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